| 注册
首页|期刊导航|世界中医药杂志(英文版)|Safety Assessment of Aconitum-Derived Bulleyaconitine A: A 91-Day Oral Toxicity Study and a Tissue Accumulation Study in Rats

Safety Assessment of Aconitum-Derived Bulleyaconitine A: A 91-Day Oral Toxicity Study and a Tissue Accumulation Study in Rats

Shi-Liang Yin Peter Breslin Chun-Fu Wu Hong Zhang Feng Xu Hao Wu Fei Li Ge Jin Zu-Qian Wu Ran Meng Si-Man Ma Fan Zhou

世界中医药杂志(英文版)2021,Vol.7Issue(2):217-226,10.
世界中医药杂志(英文版)2021,Vol.7Issue(2):217-226,10.DOI:10.4103/wjtcm.wjtcm_77_20

Safety Assessment of Aconitum-Derived Bulleyaconitine A: A 91-Day Oral Toxicity Study and a Tissue Accumulation Study in Rats

Safety Assessment of Aconitum?Derived Bulleyaconitine A: A 91?Day Oral Toxicity Study and a Tissue Accumulation Study in Rats

Shi-Liang Yin 1Peter Breslin 2Chun-Fu Wu 3Hong Zhang 3Feng Xu 3Hao Wu 3Fei Li 4Ge Jin 1Zu-Qian Wu 5Ran Meng 5Si-Man Ma 5Fan Zhou6

作者信息

  • 1. Department of Pharmacology,School of Pharmacy,Shenyang Medical College
  • 2. Depar tment of Biology and Molecular Cellular Physiology,Loyola University Chicago,Chicago,Illinois,USA
  • 3. Department of Pharmacology,School of Life Science and Biopharmaceutics,Shenyang Pharmaceutical University,Shenyang
  • 4. State Key Laboratory of Medicinal Chemical Biology,College of Pharmacy,Nankai University,Tianjin
  • 5. Department of Pharmaceutical Analysis,School of Pharmacy,Shenyang Pharmaceutical University,Shenyang
  • 6. Department of Hematology,General Hospital of Northern Theater Command,Shenyang,China
  • 折叠

摘要

Abstract

Background: Bulleyaconitine A (BLA) is a diterpenoid alkaloid from the rhizomes of Aconitum bulleyanum Diels and has been clinically used for chronic pain treatment in China for many years. However, the newly reported adverse events of BLA indicated that BLA still has potential safety issues. Materials and Methods: To assess the safety of BLA, analgesic tests, acute toxicity studies, repeated?dose oral toxicity studies, and tissue distribution studies after single and repeated administration of BLA were carried out. Results: Administration of 0.14 mg/kg BLA showed potent analgesic effects in both analgesic tests. In acute toxicity study, the LD50 value of BLA was calculated to be 3.4434 mg/kg. In the subchronic toxicity study, the no observed adverse effect level was 0.25 mg/kg, and the lowest observed adverse effect level was 0.5 mg/kg. The spleen, liver, and kidneys are newly identified target organs of BLA toxicity after long?term administration. Moreover, unlike a single BLA administration, repeated administration showed BLA redistribution from organs with an abundant blood supply to immune and metabolic organs. Conclusions: These results suggested that BLA itself would be nontoxic at a dosage of 0.25 mg/kg in rats and should be carefully used when combining BLA with medications that can cause spleen, liver, or kidney injury.

关键词

Adverse reaction/bulleyaconitine A/repeated‑dose (91‑day) toxicity/tissue distribution

Key words

Adverse reaction/bulleyaconitine A/repeated‑dose (91‑day) toxicity/tissue distribution

引用本文复制引用

Shi-Liang Yin,Peter Breslin,Chun-Fu Wu,Hong Zhang,Feng Xu,Hao Wu,Fei Li,Ge Jin,Zu-Qian Wu,Ran Meng,Si-Man Ma,Fan Zhou..Safety Assessment of Aconitum-Derived Bulleyaconitine A: A 91-Day Oral Toxicity Study and a Tissue Accumulation Study in Rats[J].世界中医药杂志(英文版),2021,7(2):217-226,10.

基金项目

This work was supported by Liao Ning Education Office(No.2019 LQN10)and Shenyang Young and middle?aged science and technology innovation program(RC180308).The author also wishes to thank Professor Bo Yuan for giving us advice on HPLC?MS/MS analysis. (No.2019 LQN10)

世界中医药杂志(英文版)

OACSTPCD

2311-8571

访问量0
|
下载量0
段落导航相关论文